NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
Clinical Trials
72 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00036868 2024-03-08
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00309478 2023-06-29
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00121992 2023-04-04
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00129389 2023-03-07
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00129922 2023-03-06
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00087178 2022-08-11
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT02400567 2022-03-15
NeoPAL
UNICANCER
Phase 2 Completed
NCT02742051 2021-09-23
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00309569 2020-10-14
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT00510367 2020-07-10
Primary Breast Cancer Occurring Concomitant With Pregnancy
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00002542 2020-04-01
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01855828 2020-03-31
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Phase 2 Completed
NCT04127019 2020-02-26
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University
Phase 3 Completed
NCT02115204 2019-10-03
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
West German Study Group
Phase 3 Completed
NCT02995772 2019-06-19
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
Dharmais National Cancer Center Hospital
Phase 3 Completed
NCT00015886 2018-08-13
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
Wake Forest University Health Sciences
Phase 2 Completed
NCT00559845 2018-04-09
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00950300 2018-01-23
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT02001506 2017-08-29
Neo-shorter
Asan Medical Center
Phase 3 Completed
NCT00331097 2017-03-28
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
National Cancer Institute, Naples
Phase 3 Completed
NCT02365805 2017-03-13
BERNAQ
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2 Completed
NCT00615901 2017-03-03
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02846428 2016-07-27
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00429299 2016-03-22
CHERLOB
GlaxoSmithKline
Phase 2 Completed
NCT00544232 2016-02-15
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
GBG Forschungs GmbH
Phase 3 Completed
NCT01204437 2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3 Completed
NCT01658033 2015-09-09
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Fudan University
Phase 2 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT02450058 2015-05-21
MIG5
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Phase 3 Completed
NCT00002870 2014-12-16
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNICANCER
Phase 3 Completed
NCT00425516 2014-10-01
Breast Cancer Treated by Neoadjuvant Chemotherapy
Centre Jean Perrin
Phase 2 Completed
NCT02225652 2014-08-26
A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT01985724 2014-05-14
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Hellenic Oncology Research Group
Phase 3 Completed
NCT00933517 2014-03-21
TVA
Centre Jean Perrin
Phase 2 Completed
NCT00003577 2013-12-19
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003893 2013-12-19
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002579 2013-11-06
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002580 2013-11-06
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002581 2013-11-06
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed